Page 81 - Human Use News Today

The drugmaker told Reuters the Committee for Medicinal Products for Human Use's (CHMP) positive opinion was an "important recognition of the unmet medical need among adolescents living with obesity and the need for additional treatment options". Argentina restarts poultry exports weeks after bird flu episode Argentina has resumed poultry shipments weeks after imposing an export ban after bird flu was detected in the local industry, state safety regulator Senasa said on Friday, pr...

The drugmaker told Reuters the Committee for Medicinal Products for Human Use's (CHMP) positive opinion was an "important recognition of the unmet medical need among adolescents living with obesity and the need for additional treatment options". Argentina restarts poultry exports weeks after bird flu episode Argentina has resumed poultry shipments weeks after imposing an export ban after bird flu was detected in the local industry, state safety regulator Senasa said on Friday, pr...

The drugmaker told Reuters the Committee for Medicinal Products for Human Use's (CHMP) positive opinion was an "important recognition of the unmet medical need among adolescents living with obesity and the need for additional treatment options". Argentina restarts poultry exports weeks after bird flu episode Argentina has resumed poultry shipments weeks after imposing an export ban after bird flu was detected in the local industry, state safety regulator Senasa said on Friday, pr...

EPYSQLI, a biosimilar referencing Soliris1 (eculizumab), is Samsung Bioepis' first biosimilar in hematology to be recommended for marketing authorization by the European Medicines Agency INCHEON, Korea

Investegate announcements from Samsung Bioepis, Samsung Bioepis Receives Positive CHMP Opinion for Eculizumab Biosimilar, EPYSQLI™

If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to <18 years in the European Union Pediatric... | March 31, 2023

Novartis AG (NVS) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Entresto (sacubitril/valsartan) for a new indication to treat symptomatic chronic heart failure with left ventricular systolic dysfunction in pediatric patients aged from 1 to <18 years.

By Colin Kellaher Bristol Myers Squibb Co. on Friday said the European Medicines Agencys Committee for Medicinal Products for Human Use has recommended approval of its CAR-T cell therapy... | March 31, 2023

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Entresto receives positive CHMP opinion for pediatric heart failure

By Colin Kellaher TG Therapeutics Inc. on Friday said the European Medicines Agencys Committee for Medicinal Products for Human Use has recommended approval of Briumvi for the treatment of... | March 31, 2023